Core Insights - A joint team from Osaka University and Ehime University has discovered a low molecular compound that can temporarily "open" the blood-brain barrier, enhancing the delivery and efficacy of drugs for brain diseases [1][2] Group 1: Blood-Brain Barrier and Its Challenges - The blood-brain barrier is a specialized physiological structure that selectively prevents harmful substances in the blood from entering brain tissue while allowing essential substances like oxygen and glucose to pass through [1] - The existence of the blood-brain barrier poses significant challenges for drug delivery in treating brain diseases, making it difficult for therapeutic agents to reach affected areas [1] Group 2: Discovery and Characteristics of CL5B - The research team screened approximately 9,600 substances to identify several that can penetrate the blood-brain barrier, ultimately confirming a compound named "CL5B" [1] - CL5B can rapidly "open" the blood-brain barrier and control the "opening" duration to within 30 minutes, facilitating safer drug delivery to brain lesions [1] Group 3: Efficacy in Animal Trials - In trials using rats with epilepsy, the combination of CL5B and therapeutic drugs was found to be more effective in suppressing seizures compared to administering the treatment alone, demonstrating the efficacy of CL5B [2] - The compound CL5B shows potential for developing new combination therapies for high-mortality brain tumors and may also play a positive role in treating Alzheimer's disease and Parkinson's disease [2]